title: Optimized sample preparation strategy for the analysis of low molecular mass adducts of a fluorescent cisplatin analogue in cancer cell lines by CE-dual-LIF.
abstract: Pt-based anticancer drugs, such as cisplatin, are known to undergo several (bio-)chemical transformation steps after administration. Hydrolysis and adduct formation with small nucleophiles and larger proteins are their most relevant reactions on the way to the final reaction site (DNA), but there are still many open questions regarding the identity and pharmacological relevance of various proposed adducts and intermediates. Furthermore, the role of buffer components or additives, which are inevitably added to samples during any type of analytical measurement, has been frequently neglected in previous studies. Here, we report on adduct formation reactions of the fluorescent cisplatin analogue carboxyfluorescein diacetate platinum (CFDA-Pt) in commonly used buffers and cell culture medium. Our results indicate that chelation reactions with noninnocent buffers (e.g., Tris) and components of the cell culture/cell lysis medium must be taken into account when interpreting results. Adduct formation kinetics was followed up to 60 h at nanomolar concentrations of CFDA-Pt by using CE-LIF. CE-MS enabled the online identification of such unexpected adducts down to the nanomolar concentration range. By using an optimized sample preparation strategy, unwanted adducts can be avoided and several fluorescent adducts of CFDA-Pt are detectable in sensitive and cisplatin-resistant cancer cell lines. By processing samples rapidly after incubation, we could even identify the initial, but transient, Pt species in the cells as deacetylated CFDA-Pt with unaltered complexing environment at Pt. Overall, the proposed procedure enables a very sensitive and accurate analysis of low molecular mass Pt species in cancer cells, involving a fast CE-LIF detection within 5 min.
authors.affiliation: Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V, Dortmund, Germany.
authors.forename: Robert
authors.initials: R
authors.lastname: Zabel
authors.forename: Maximilian
authors.initials: M
authors.lastname: Kullmann
authors.forename: Ganna V
authors.initials: GV
authors.lastname: Kalayda
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jaehde
authors.forename: Günther
authors.initials: G
authors.lastname: Weber
mesh_terms: D000970:Antineoplastic Agents / Q000032:analysis / Q000737:chemistry; D002021:Buffers; D045744:Cell Line, Tumor / Q000187:drug effects; D002945:Cisplatin / Q000031:analogs & derivatives* / Q000032:analysis / Q000737:chemistry; D018736:DNA Adducts / Q000032:analysis*; D019075:Electrophoresis, Capillary / Q000295:instrumentation / Q000379:methods*; D005452:Fluoresceins / Q000032:analysis*; D005456:Fluorescent Dyes / Q000032:analysis / Q000737:chemistry; D006801:Humans; D054023:Lasers, Semiconductor; D008970:Molecular Weight; D021241:Spectrometry, Mass, Electrospray Ionization
chemical_list: D000970:Antineoplastic Agents; D002021:Buffers; D018736:DNA Adducts; D005452:Fluoresceins; D005456:Fluorescent Dyes; C027780:carboxyfluoresceindiacetate; D002945:Cisplatin
keywords: CE-LIF; Cancer cell lines; Fluorescent cisplatin analogue; Platinum adducts